Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1261)	7/27/1999 8:41:00 AM
From: William Partmann	Read Replies (1) \| Respond to of 1580

July 27 (Reuters) - Irish pharmaceuticals group Elan Corp Plc (quote from Yahoo! UK & Ireland: ELA.L)(NYSE:ELN - news) said on Tuesday it had signed a technology transfer and license agreement with U.S. group Merck & Co on Elan's NanoCrystal technology. Elan said it would receive up to $30 million in pre-commercialisation payments, milestone fees and royalties and sales of products formulated using its technology. The technology improves the delivery of poorly water-soluble medicines by transforming the drug compounds into nanometer-sized particles that can be used in traditional forms of dosage, including oral, injectable, and aerosol.